Novartis names new US pharma chief

Share this article:
Novartis confirmed in published reports today that it has appointed Ludwig Hantson to head its US pharmaceuticals business. 

Hantson reports to Joe Jimenez, CEO of the Basel, Switzerland-based company's pharmaceutical business. Hantson replaces Alex Gorsky, who announced he was leaving Novartis in February. 
Hantson most recently served as head of Novartis' specialty pharmaceuticals unit in the US, where he has worked since December 2006. 

Novartis also said Paulo Costa, president and CEO of Novartis' US unit, will retire June 30 and be replaced by Gary Rosenthal. Rosenthal is currently CFO of the US pharmaceuticals business. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...